• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.210 -0.050 (-3.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 996,043
Open 1.250
Bid (Size) 1.210 (100)
Ask (Size) 1.230 (500)
Prev. Close 1.260
Today's Range 1.190 - 1.265
52wk Range 1.190 - 5.200
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
Company initiates search for successor 
From MaxCyte, Inc
Via GlobeNewswire

Performance

YTD
-21.9%
-21.9%
1 Month
-25.8%
-25.8%
3 Month
-29.2%
-29.2%
6 Month
-46.0%
-46.0%
1 Year
-76.3%
-76.3%

More News

Read More
News headline image
Earnings Scheduled For November 12, 2025 ↗
November 12, 2025
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
November 05, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
August 06, 2025
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
May 07, 2025
Via Benzinga
News headline image
A Look at MaxCyte's Upcoming Earnings Report ↗
May 06, 2025
Via Benzinga
News headline image
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Insights into MaxCyte's Upcoming Earnings ↗
November 11, 2025
Via Benzinga
News headline image
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 05, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 08, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
October 06, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
September 22, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
August 11, 2025
Via Benzinga
News headline image
Thursday's session: top gainers and losers ↗
August 07, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
August 07, 2025
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
August 07, 2025
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
August 07, 2025
Via Chartmill
News headline image
MaxCyte (MXCT) Q2 Revenue Drops 18% ↗
August 06, 2025
Via The Motley Fool
News headline image
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 06, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Platform License Agreement with Adicet Bio
August 04, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
July 31, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
July 09, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
June 11, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
May 07, 2025
From MaxCyte, Inc
Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 1.210
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 01/20/26 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 127.63M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 128M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap